Cantor Fitzgerald reiterates Vaxcyte stock rating on OPUS-1 data
Cantor Fitzgerald reiterated an Overweight rating on Vaxcyte (PCVX) with a $120 price target, citing OPUS-1 data and $1B financing. The firm raised adult success probability to 90% and noted potential upside to $90. The stock has declined 10% in a week but gained 50% over a year. Multiple analysts updated targets post-trial results.
How this was made
The 30-second read
Why it matters
The new data increased adult success probability to 90% and led Cantor to raise its price target, indicating potential upside.
Market read
Analyst upgrades on fresh trial data can drive short‑term price moves in biotech equities.
What to watch
Financing pressure and delayed pediatric readout could temper upside.
Background
Vaxcyte (PCVX) reported top‑line results from its OPUS‑1 vaccine trial, prompting multiple analyst target revisions.
Ticker impact
Cantor Fitzgerald reiterated an Overweight rating and set a $120 price target after Vaxcyte's OPUS-1 trial results and $1 billion financing.
likely upward as market prices in the new $120 target
The rating change and target raise are fresh, material information for a biotech with a pivotal trial.
Market effects
Positive sentiment may lift other biotech stocks awaiting trial data.
US biotech sector could see modest gains.
Limited to investors focused on clinical‑trial outcomes.
Counterpoint
Some investors may wait for pediatric data before committing.
Key entities
- companyVaxcyte
Biotech developing the VAX‑31 vaccine.
- analystCantor Fitzgerald
Equity research firm that issued the rating and target.
